Bernard Aral
Centre national de la recherche scientifique
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Bernard Aral.
Pediatric Research | 2001
Pascale de Lonlay; Chantal Benelli; Françoise Fouque; Arupa Ganguly; Bernard Aral; Carlo Dionisi-Vici; Guy Touati; Claire Heinrichs; Daniel Rabier; P. Kamoun; Jean-Jacques Robert; Charles A. Stanley; Jean-Marie Saudubray
Hyperinsulinism and hyperammonemia syndrome has been reported as a cause of moderately severe hyperinsulinism with diffuse involvement of the pancreas. The disorder is caused by gain of function mutations in the GLUD1 gene, resulting in a decreased inhibitory effect of guanosine triphosphate on the glutamate dehydrogenase (GDH) enzyme. Twelve unrelated patients (six males, six females) with hyperinsulinism and hyperammonemia syndrome have been investigated. The phenotypes were clinically heterogeneous, with neonatal and infancy-onset hypoglycemia and variable responsiveness to medical (diazoxide) and dietary (leucine-restricted diet) treatment. Hyperammonemia (90–200 μmol/L, normal <50 μmol/L) was constant and not influenced by oral protein, by protein- and leucine-restricted diet, or by sodium benzoate or N-carbamylglutamate administration. The patients had mean basal GDH activity (18.3 ± 0.9 nmol/min/mg protein) not different from controls (17.9 ± 1.8 nmol/min/mg protein) in cultured lymphoblasts. The sensitivity of GDH activity to inhibition by guanosine triphosphate was reduced in all patient lymphoblast cultures (IC50, or concentrations required for 50% inhibition of GDH activity, ranging from 140 to 580 nM, compared with control IC50 value of 83 ± 1.0 nmol/L). The allosteric effect of ADP was within the normal range. The activating effect of leucine on GDH activity varied among the patients, with a significant decrease of sensitivity that was correlated with the negative clinical response to a leucine-restricted diet in plasma glucose levels in four patients. Molecular studies were performed in 11 patients. Heterozygous mutations were localized in the antenna region (four patients in exon 11, two patients in exon 12) as well as in the guanosine triphosphate binding site (two patients in exon 6, two patients in exon 7) of the GLUD1 gene. No mutation has been found in one patient after sequencing the exons 5–13 of the gene.
Human Mutation | 1996
Bernard Aral; Geneviève de Saint Basile; Sami Al-Garawi; P. Kamoun; Irène Ceballos-Picot
Lesch‐Nyhan (LN) disease is a severe X‐linked recessive neurological disorder associated with a loss of hypoxanthine guanine phosphoribosyltransferase activity (HPRT, EC 2.4.2.8). We have studied the second example of a female patient with LN disease. The molecular basis of HPRT deficiency in this patient was a previously undescribed nucleotide substitution in exon 6. In this gene, designated HPRT PARIS, a single nucleotide substitution from T to G at base position 558 changed a tyrosine (TAT) to a codon STOP (TAG) (Y153X). Analysis of the mother revealed a normal sequence of the HPRT cDNA and demonstrated that this mutation arose through a de novo gametic event. Allele‐specific amplification of exon 6 from the patients genomic DNA confirmed the single base substitution and showed that the patient was heterozygous for this mutation. Investigation of X‐chromosomal inactivation by comparison of methylation patterns of patients DNA isolated from fibroblasts, T lymphocytes, and polymorphonuclear cells digested with PstI and BstXI, with or without HpaII, and hybridized with M27 β probe indicated a nonrandom pattern of X‐chromosomal inactivation in which there was preferential inactivation of the maternal allele. The data indicate that nonrandom X‐inactivation leading to selective inactivation of the maternal gene and a de novo point mutation in the paternal gene were responsible for the lack of HPRT activity in this patient.
Annals of Neurology | 2003
Runu Dey; Manuele Mine; Isabelle Desguerre; Abdelhamid Slama; Loic Van Den Berghe; Michèle Brivet; Bernard Aral; Cécile Marsac
We report a case of neonatal congenital lactic acidosis associated with pyruvate dehydrogenase E3‐binding protein deficiency in a newborn girl. She had a severe encephalopathy, and magnetic resonance imaging of the brain showed large subependymal cysts and no basal ganglia lesions. She died 35 days after birth. We detected a novel homozygous deletion (620delC) in the PDX1 gene, which encodes for the E3BP subunit of the pyruvate dehydrogenase complex.
Molecular Genetics and Metabolism | 2002
Runu Dey; Bernard Aral; Marc Abitbol; Cécile Marsac
Mutations in the E3-binding protein component of pyruvate dehydrogenase complex have been demonstrated in a few cases of Leigh syndrome. We report that two mutations previously detected in the E3-binding protein cDNA are the consequence of splice-site mutations. Both involved a single base substitution in the conserved dinucleotides of splice junctions, one leading to skipping of an exon and the other, to activation of a cryptic site. Our findings add to the understanding of molecular basis of E3-binding protein deficiency and indicate yet again the high frequency of splicing mutations in this gene.
Molecular Genetics and Metabolism | 2013
Irène Ceballos-Picot; Franck Augé; Rong Fu; Anne Olivier-Bandini; Julie Cahu; Brigitte Chabrol; Bernard Aral; Bérengère de Martinville; Jean-Paul Lecain; H.A. Jinnah
We describe a family of seven boys affected by Lesch-Nyhan disease with various phenotypes. Further investigations revealed a mutation c.203T>C in the gene encoding HGprt of all members, with substitution of leucine to proline at residue 68 (p.Leu68Pro). Thus patients from this family display a wide variety of symptoms although sharing the same mutation. Mutant HGprt enzyme was prepared by site-directed mutagenesis and the kinetics of the enzyme revealed that the catalytic activity of the mutant was reduced, in association with marked reductions in the affinity towards phosphoribosylpyrophosphate (PRPP). Its Km for PRPP was increased 215-fold with hypoxanthine as substrate and 40-fold with guanine as substrate with associated reduced catalytic potential. Molecular modeling confirmed that the most prominent defect was the dramatically reduced affinity towards PRPP. Our studies suggest that the p.Leu68Pro mutation has a strong impact on PRPP binding and on stability of the active conformation. This suggests that factors other than HGprt activity per se may influence the phenotype of Lesch-Nyhan patients.
American Journal of Human Genetics | 1997
Bernard Aral; Chantal Benelli; Ghania Ait-Ghezala; Mohamed Amessou; Françoise Fouque; Catherine Maunoury; Nicole Créau; Pierre Kamoun; C. Marsac
Human Mutation | 1997
Bernard Aral; Marie Coudé; Jacqueline London; Joelle Aupetit; Jean-François Chassé; Marie-Thérèse Zabot; Bernadette Chadefaux-Vekemans; Pierre Kamoun
Genomics | 1996
Guang Liu; Catherine Maunoury; Pierre Kamoun; Bernard Aral
Human Mutation | 1998
Guang Liu; Bernard Aral; Marie-Thérèse Zabot; Pierre Kamoun; Irène Ceballos-Picot
Archive | 1998
Guang Liu; Bernard Aral; Marie-Thkritse Zabot; P. Kamoun; Irhe Ceballos-Picot